DEEP 6 AI Secures $2.5M in Funding to Revolutionize Clinical Trial Enrollment

Deep 6 AI, a trailblazer in transforming the clinical trial enrollment landscape, has successfully raised $2,500,000 in its latest funding round.

Since its inception in 2015, the Pasadena-based company has harnessed the power of artificial intelligence and natural language processing to streamline the process of patient identification for clinical trials.

By effectively mining both structured and unstructured patient data, Deep 6 AI enables researchers to identify eligible patients in mere minutes, a stark contrast to the traditional process that often takes months.

This revolutionary platform is already recognized by some of the world’s leading health systems, pharmaceutical companies, and contract research organizations (CROs), making the DEEP 6 solution an invaluable asset in their clinical research workflows.

The newly secured funding will empower Deep 6 AI to enhance its platform’s capabilities further, expand its reach within the clinical research community, and accelerate patient access to potentially life-saving clinical trials.

As the demand for rapid patient recruitment continues to grow, Deep 6 AI's innovative approach positions it as a key player in reshaping the future of clinical research and improving patient outcomes.

With this fresh capital, Deep 6 AI is committed to pushing the boundaries of how clinical trials are conducted, offering hope for faster, more efficient pathways to new therapies for patients in need.